The life sciences sector is uniquely capital-intensive, highly regulated, and driven by continuous innovation. Pharmaceutical manufacturers, biotechnology firms, medical device companies, and contract research organizations (CROs) routinely invest tens or hundreds of millions of dollars into highly specialized facilities designed to support research, testing, manufacturing, and quality assurance activities.
While tax planning conversations in life sciences frequently center on the R&D tax credit, orphan drug incentives, and transaction structuring, cost segregation remains one of the most effective tools for improving after-tax cash flow and accelerating return on invested capital.
When executed correctly, cost segregation complements other federal incentives, such as the R&D Tax Credit, the §179D Energy-Efficient Commercial Building Deduction, and the Orphan Drug Tax Credit (ODTC), to create a layered tax strategy tailored to life science organizations.
Understanding Cost Segregation in a Life Sciences Context
Cost segregation is an engineering-based tax analysis that dissects a building’s construction or acquisition costs to identify components eligible for shorter recovery periods under the Internal Revenue Code (IRC). Instead of depreciating an entire facility over 39 years, qualifying assets are reclassified into 5-, 7-, or 15-year property, accelerating depreciation deductions under IRC §168.
For life science companies already leveraging incentives such as the R&D Tax Credit (for qualified research activities and related wage/supply costs), cost segregation introduces a complementary lever: non-credit depreciation deductions that reduce taxable income and improve near-term cash flow.
Why Life Science Facilities Are Ideal Candidates
The cost per square foot associated with equipping a life sciences property is higher than that associated with fitting out any other type of commercial real estate. This makes the sector one of the highest-leverage candidates for cost segregation.
Life science buildings are purpose-built environments engineered around scientific precision, regulatory compliance, and process-driven design. These characteristics distinguish them from conventional commercial properties and materially expand cost segregation opportunities.
Typical features include:
-
u003cliu003eHighly specialized mechanical, electrical, and plumbing (MEP) systems u003c/liu003eu003cliu003eProcess-specific infrastructure supporting Ru0026amp;D and regulated production u003c/liu003eu003cliu003eRedundant environmental controls and monitoring u003c/liu003eu003cliu003eEquipment-driven layouts and dedicated support utilities u003c/liu003e
From a tax standpoint, many of these assets can be treated as personal property (rather than structural components) when they are installed primarily to support equipment, processes, or specialized operational requirements.
High-Value Asset Categories Common in Life Science Cost Segregation
1. Specialized HVAC and Environmental Control Systems
Life science facilities often require HVAC systems that exceed standard building requirements due to cleanroom classification, product stability requirements, or compliance-driven environmental parameters. These may include:
-
u003cliu003eCleanroom-rated air handling units (AHUs) u003c/liu003eu003cliu003eHEPA filtration and pressure cascade systems u003c/liu003eu003cliu003eRedundant ventilation/exhaust and specialty airflows u003c/liu003eu003cliu003eTemperature/humidity controls tied to research or manufacturing protocols u003c/liu003e
When these systems serve specific labs, suites, or controlled zones, portions can often be classified into shorter recovery lives, particularly where design intent is process-driven rather than general occupant comfort.
Internal cross-link opportunity: These same HVAC and lighting efficiency upgrades may also support eligibility under the §179D Energy-Efficient Commercial Building Deduction, enabling a coordinated approach between energy incentives and depreciation planning.
2. Laboratory Build-Outs and Process Infrastructure
Laboratory-intensive environments represent some of the strongest cost segregation value drivers for life sciences. Reclassifiable assets often include:
-
u003cliu003eFixed and modular lab casework and specialty furniture u003c/liu003eu003cliu003eProcess piping (medical gases, specialty gases, compressed air, RO/DI water, purified water) u003c/liu003eu003cliu003eDedicated electrical distribution supporting lab equipment loads u003c/liu003eu003cliu003eFume hoods, exhaust systems, and ancillary monitoring systems u003c/liu003e
Because these assets are designed to support R&D operations, they commonly align with documentation and technical narratives already developed for the R&D Tax Credit, creating efficiency in substantiation and data collection.
3. Cleanrooms and Controlled Manufacturing Environments
Cleanrooms, especially in pharmaceutical, biologics, and medical device production are frequently among the most tax-efficient components of life science facilities when analyzed through cost segregation.
Eligible components may include:
-
u003cliu003eModular wall/ceiling systems and removable partitions u003c/liu003eu003cliu003eRaised access flooring and airflow control systems u003c/liu003eu003cliu003eEnvironmental monitoring/controls and validation-adjacent infrastructure u003c/liu003eu003cliu003eProcess-specific lighting and electrical infrastructure u003c/liu003e
These assets are often product-line specific, removable, or directly tied to operational processes, which can strengthen support for classification as personal property.
4. Electrical, Data, and Automation Systems
Life science operations demand electrical and data infrastructure beyond standard commercial requirements, including:
-
u003cliu003eDedicated panels/transformers serving specialized equipment u003c/liu003eu003cliu003eBackup power and emergency circuits for critical loads u003c/liu003eu003cliu003eBuilding automation systems (BAS) integrated with controlled spaces u003c/liu003eu003cliu003eData and monitoring cabling supporting compliance and operational oversight u003c/liu003e
The portion of these systems dedicated to equipment operation and specialized process support can often be segregated into shorter lives, depending on design intent and system allocation.
5. Site and Exterior Improvements
Life science campuses frequently include extensive site-level investments:
-
u003cliu003eUtility distribution and specialty waste handling support u003c/liu003eu003cliu003eSecure access roads, screening, and controlled loading areas u003c/liu003eu003cliu003eEquipment pads, exterior enclosures, and service yards u003c/liu003e
These costs are often eligible for 15-year depreciation as land improvements, accelerating cost recovery compared to default structural capitalization.
Timing and Method Change Considerations (Without Relying on Bonus Depreciation)
Cost segregation can deliver value in multiple scenarios:
-
u003cliu003eu003cstrongu003eNew constructionu003c/strongu003e (ground-up lab, GMP/GLP expansions, campus buildouts) u003c/liu003eu003cliu003eu003cstrongu003eAcquisitionsu003c/strongu003e (facility purchase price allocations with embedded short-life assets) u003c/liu003eu003cliu003eu003cstrongu003eRenovations and tenant improvementsu003c/strongu003e (lab conversions, cleanroom retrofits, MEP upgrades) u003c/liu003eu003cliu003eu003cstrongu003eExisting propertiesu003c/strongu003e (where a “lookback” study may support a catch-up adjustment via accounting method change, depending on facts and filing posture) u003c/liu003e
For life science organizations that scale quickly or frequently reconfigure space to meet program and pipeline needs, proactive cost segregation planning can prevent value leakage by ensuring asset classes are documented and captured correctly at the time of placement in service.
One Big Beautiful Bill Act (2025), A Game Changer
The OBBBA introduces significant changes to 100% bonus depreciation, making it permanent for most property acquired after January 19, 2025, and establishing a new temporary allowance for qualified production property, defined as non-residential building property with a 39-year depreciable life used integrally in qualified production activities and placed in service in the U.S. This is particularly impactful for pharma and medtech manufacturers building or expanding domestic facilities.
Integrating Cost Segregation with Broader Life Science Tax Strategy
Cost segregation is strongest when evaluated as part of a portfolio-wide incentive strategy. For life science companies, that often includes:
-
u003cliu003eThe u003cstrongu003eRu0026amp;D Tax Creditu003c/strongu003e (research activities, technical narratives, cost tracing) u003c/liu003eu003cliu003eThe u003cstrongu003e§179D deductionu003c/strongu003e (energy-efficient building systems and design strategies) u003c/liu003eu003cliu003eThe u003cstrongu003eOrphan Drug Tax Credit (ODTC)u003c/strongu003e (when applicable to qualifying rare disease therapies and associated development costs) u003c/liu003e
Internal cross-link opportunity: If you’re already evaluating ODTC impacts in late-stage valuations and deal models, cost segregation can improve after-tax cash flow projections by accelerating depreciation recovery on specialized facilities supporting clinical and commercial scale-up.
IRS Scrutiny and the Importance of Technical Rigor
Given the complexity and dollar magnitude of life science facilities, cost segregation studies must be performed using a defensible, engineering-based methodology. Best practices include:
-
u003cliu003eDetailed cost breakdowns tied to invoices, pay apps, and schedules of values u003c/liu003eu003cliu003eReview of as-built drawings, specifications, and equipment schedules u003c/liu003eu003cliu003eAsset-level classification support and allocation logic u003c/liu003eu003cliu003eCoordination between tax, facilities, engineering, and finance teams u003c/liu003e
Studies lacking technical substantiation (or relying on overly broad heuristics) can increase audit exposure, especially in highly specialized environments like cleanrooms and regulated manufacturing suites.
Conclusion: A Strategic Advantage for Life Science Organizations
For many life science companies, cost segregation remains an overlooked opportunity, often due to misconceptions about eligibility or perceived complexity. In reality, the very features that make life science facilities expensive to build also make them prime candidates for accelerated depreciation.
For life science companies, cost segregation is a capital efficiency tool disguised as a tax strategy. The specialized, high-cost nature of lab and manufacturing buildouts means more assets qualify for reclassification than in almost any other property type. Combined with permanent 100% bonus depreciation under the OBBBA, the program can meaningfully accelerate cash return on capital, which is especially critical for pre-revenue biotech firms burning through capital on R&D and infrastructure simultaneously.
When strategically integrated with R&D credits, §179D energy incentives, and (where applicable) orphan drug incentives, cost segregation becomes a powerful lever for improving cash flow, increasing capital efficiency, and supporting innovation-driven growth.